TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04147377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral intervention based on sensory cues
Description: Patients will receive behavior intervention training that includes how to apply visual and auditory cues to freezing of gait in real clinical practice.
Study: NCT03136146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposome
Description: Given IV
Study: NCT04452071

Intervention type: RADIATION
Intervention: periapical xray
Description: periapical xray on the middle phalanax of the middle finger

Intervention type: RADIATION
Intervention: periapical xray
Description: periapical xray on the middle phalanax of the middle finger

Intervention type: RADIATION
Intervention: periapical xray
Description: periapical xray on the middle phalanax of the middle finger
Study: NCT01212679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nerve growth factor
Description: The experimental group patients will receive NGF 20ug/d intranasally for 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nomral saline
Description: The Placebo Comparator group patients will receive nomral saline 20ug/d intranasally for 2 weeks.
Study: NCT04699032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apraglutide
Description: Single dose of apraglutide 5 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apraglutide
Description: Single dose of apraglutide 5 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apraglutide
Description: Single dose of apraglutide 5 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apraglutide
Description: Single dose of apraglutide 5 mg.
Study: NCT03383913

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability Biofeedback
Description: Over a period of 4-6 weeks participants in the intervention arm will learn a series of breathing techniques to determine Heart Rate Variability's effects on physical function, anxiety, depression, fatigue, sleep disturbance, participation in social activities, pain interference and intensity.
Study: NCT02402127

Intervention type: DEVICE
Group type: OTHER
Intervention: Stenfilcon A contact lenses
Description: Silicone hydrogel contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Somofilcon A contact lenses
Description: Silicone hydrogel contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Somofilcon A contact lenses
Description: Silicone hydrogel contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Somofilcon A contact lenses
Description: Silicone hydrogel contact lenses for daily disposable wear
Study: NCT02823028

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NRT
Description: 8-weeks of study provided NRT patch, and 8-weeks of study provided NRT gum of varying strengths or 8-weeks of study provided NRT lozenges, depending on patient level of nicotine dependence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRT
Description: 8-weeks of study provided NRT patch, and 8-weeks of study provided NRT gum of varying strengths or 8-weeks of study provided NRT lozenges, depending on patient level of nicotine dependence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRT
Description: 8-weeks of study provided NRT patch, and 8-weeks of study provided NRT gum of varying strengths or 8-weeks of study provided NRT lozenges, depending on patient level of nicotine dependence.
Study: NCT02744118

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5A's Model
Description: The adapted 5A's model will include the following elements:~1. Ask the patient about their marijuana use~2. Advise every patient to quit/reduce marijuana use using clear, specific personalized advice~3. Assess factors affecting choice of behavior and behavior change~4. Assist abstinence/reduction in in marijuana use using behavior change techniques to aid the patient~5. Arrange follow-up for ongoing assistance and support, and to adjust treatment plans

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Internet Use Model
Description: The Healthy Internet Use Model provides a framework for conversations between pediatric practitioners and their adolescent patients. It focuses on 3 key areas of social media behavior:~1. Balance~2. Boundaries~3. Communication
Study: NCT02591186

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Participants will receive 3 acupuncture sessions during IVF process
Study: NCT02391129

Intervention type: PROCEDURE
Intervention: Operation for Periprosthetic fractures of the hip with stem loosening

Intervention type: PROCEDURE
Intervention: Operation for Periprosthetic fractures of the hip with stem loosening

Intervention type: PROCEDURE
Intervention: Operation for Periprosthetic fractures of the hip with stem loosening
Study: NCT00620399

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lumbar corset

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: lumbar corset
Study: NCT03016377

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iC9-CAR19 cells
Description: Three dose levels are being evaluated: dose level -1 (1 x 10\^5), dose level 1 (5 x 10\^5), and dose level 2 ( 1x 10\^6)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iC9-CAR19 cells
Description: Three dose levels are being evaluated: dose level -1 (1 x 10\^5), dose level 1 (5 x 10\^5), and dose level 2 ( 1x 10\^6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: Subjects with CRS and ICAN will assign one of two dose levels (DL)s of rimiducid with the standard treatment: 0.05 mg/kg or 0.1 mg/kg for subjects with CRS and 0.01mg/kg or 0.1mg/kg for subjects with ICAN. Subjects will first be enrolled on DL 1 and then enrolled on DL 2, and 0.4mg/kg rimiducid will be given to subjects who did not respond to the initial dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: Subjects with CRS and ICAN will assign one of two dose levels (DL)s of rimiducid with the standard treatment: 0.05 mg/kg or 0.1 mg/kg for subjects with CRS and 0.01mg/kg or 0.1mg/kg for subjects with ICAN. Subjects will first be enrolled on DL 1 and then enrolled on DL 2, and 0.4mg/kg rimiducid will be given to subjects who did not respond to the initial dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 900 mg/m\^2 IV over 1 hour on day 4 of lymphodepleting chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 900 mg/m\^2 IV over 1 hour on day 4 of lymphodepleting chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2/day IV over 30 minutes administered for 3 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2/day IV over 30 minutes administered for 3 consecutive days.
Study: NCT02589652

Intervention type: DRUG
Intervention: Pegylated interferon alfa-2a
Description: ETV 0.5mg oral daily plus PegIFN alfa-2a 180ug subcutaneous injection weekly for 8 weeks and followed by PegIFN alfa-2a 180ug subcutaneous injection weekly for 40 weeks

Intervention type: DRUG
Intervention: Pegylated interferon alfa-2a plus Entecavir
Description: ETV 0.5mg oral daily plus PegIFN alfa-2a 180ug subcutaneous injection weekly for 48 weeks

Intervention type: DRUG
Intervention: Entecavir
Description: ETV 0.5mg oral daily for 48 weeks
Study: NCT03066700

Intervention type: DEVICE
Intervention: Hemostatic powder
Description: HemosprayTM (Tc-325) is an endoscopic hemostatis powder that came onto market recently. It is made of an inorganic, non-absorbable powder which acts locally at the mucosa. When spraying the powder on to the bleeding site, it creates an adherent stable barrier sheath that allows for at least temporary hemostasis. Neither luminal nor systemic side effects have been reported to date.
Study: NCT03365258

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Trophic feeding
Description: Non-blind to randomize to trophic feeding group and volume based feeding group in the first six days (Day 0-\>Day 6). The definition of trophic feeding is continue feeding with feeding rate: 20 kcal/hr.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Trophic feeding
Description: Non-blind to randomize to trophic feeding group and volume based feeding group in the first six days (Day 0-\>Day 6). The definition of trophic feeding is continue feeding with feeding rate: 20 kcal/hr.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: volume-based feeding
Description: Non-blind to randomize to trophic feeding group and volume based feeding group in the first six days (Day 0-\>Day 6). The definition Volume-based feeding also use continue feeding by feeding protocol

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: volume-based feeding
Description: Non-blind to randomize to trophic feeding group and volume based feeding group in the first six days (Day 0-\>Day 6). The definition Volume-based feeding also use continue feeding by feeding protocol
Study: NCT03269968

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (PREVENA Incision Management Therapy System)
Description: After cesarean delivery, women in the intervention group will receive PREVENA Incision Management Therapy System.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard dressing
Description: After cesarean delivery, women in the intervention group will receive standard dressing.
Study: NCT01096368

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Patients undergo conformal radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Patients undergo conformal radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Patients undergo conformal radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Observation
Description: Patients undergo observation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT02402127

Intervention type: DEVICE
Group type: OTHER
Intervention: Somofilcon A contact lenses
Description: Silicone hydrogel contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Somofilcon A contact lenses
Description: Silicone hydrogel contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Somofilcon A contact lenses
Description: Silicone hydrogel contact lenses for daily disposable wear
Study: NCT02980887

Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention in this observational study

Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention in this observational study

Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention in this observational study
Study: NCT01096368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT01697930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] 4-L-Fluoroglutamine (2S,4R)
Description: Thirty cancer patients will receive an injection of a 0.5 to 7.5mCi of \[18F\] 4-LFluoroglutamine (2S,4R) , followed by serial PET/CT scanning and blood draws, (at the direction of the investigator) over a period of 3.5 hours, on a single day. Each patient will be offered the opportunity to repeat the \[18F\] 4-L-Fluoroglutamine (2S,4R) injection and subsequent set of post-injection PET-CT scans, once, on a separate date. At the discretion of the investigator, scan 3 can be waived. Immediately prior to injection of the radiotracer, a blood sample will be obtained for measurement of serum glutamine level. The serum glutamine level will be assayed, if necessary, as part of an amino acid screen assay.
Study: NCT04473963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrographic Flow™ guided ablation
Description: In addition to standard pulmonary vein isolation (PVI) or PVI touch-up, subjects receive targeted radiofrequency source ablation guided by Electrographic Flow™ (EGF) mapping. EGF mapping enables the full spatiotemporal reconstruction of organized atrial electrical wavefront propagation to identify active sources or origins of excitation that may trigger atrial fibrillation (AF).~EGF mapping involves 1 minute recordings of unipolar electrograms from a basket catheter, which are then processed with the EGF software. Several basket catheter positions are acquired in standard positions in both the left and right atria. EGF-identified sources with activity above the threshold (≥ 26.5%) are considered significant and targeted for ablation. The procedure concludes when all EGF-identified sources are eliminated, defined as reducing source activity below the threshold.
Study: NCT01096368

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: Given SC or IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC or IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC or IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesna
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study: NCT01445509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Once the MTD of dasatinib with bevacizumab 5 mg/kg IV every two weeks is determined, one final dose level will be accrued with that MTD dose of dasatinib with bevacizumab at 10 mg/kg IV every two weeks in order to determine if we can safely escalate bevacizumab to full dose with dasatinib concurrently.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Once the MTD of dasatinib with bevacizumab 5 mg/kg IV every two weeks is determined, one final dose level will be accrued with that MTD dose of dasatinib with bevacizumab at 10 mg/kg IV every two weeks in order to determine if we can safely escalate bevacizumab to full dose with dasatinib concurrently.
Study: NCT00881582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a plus ribavarin
Description: PEG-interferon alfa-2a and ribavirin. Pegylated interferon alfa-2a - standard dose; plus ribavirin - standard dose (determined by creatinine clearance); for 24 to 48 weeks (genotypes 1 \& 4: 48 weeks; genotypes 2 \& 3: 24 weeks)
Study: NCT01445509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: We will start dasatinib at 50 mg PO QD which is less than half the recommended Phase 2 dose as well as bevacizumab at 5 mg/kg IV every two weeks, which is half the single agent dose. If this is well-tolerated, study drugs will be escalated per schema to maximize the dose of dasatinib when given concurrently.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: We will start dasatinib at 50 mg PO QD which is less than half the recommended Phase 2 dose as well as bevacizumab at 5 mg/kg IV every two weeks, which is half the single agent dose. If this is well-tolerated, study drugs will be escalated per schema to maximize the dose of dasatinib when given concurrently.
Study: NCT02231775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Given PO
Study: NCT03752580

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: User Instructions of novel nasal mask
Description: User Unstructions interpretation of novel nasal mask for the treatment of obstructive sleep apnea (OSA).
Study: NCT01904591

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium
Description: Selenium 50 micrograms daily per oral~1 year of treatment

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Vitamin E 400 international units daily per oral~1 year of treatment
Study: NCT01150864

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airway Conditioning
Description: Each Passive device will be changed daily. When using Active and Passive devices as well as Active-Passive devices the ventilatory circuit will be changed every 7 days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airway Conditioning
Description: Each Passive device will be changed daily. When using Active and Passive devices as well as Active-Passive devices the ventilatory circuit will be changed every 7 days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airway Conditioning
Description: Each Passive device will be changed daily. When using Active and Passive devices as well as Active-Passive devices the ventilatory circuit will be changed every 7 days.
Study: NCT02231775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study: NCT03862781

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Right Hemicolectomy
Description: Minimally invasive approach (robotic or laparoscopic) with the creation of an anastomosis.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Right Hemicolectomy
Description: Minimally invasive approach (robotic or laparoscopic) with the creation of an anastomosis.
Study: NCT03305653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal String Test (EST)
Description: The EST is a gelatin capsule filled with a 90cm nylon string. A trailing end of the string protrudes from one end of the capsule. This end is taped to the cheek and the capsule is swallowed. As the capsule travels to the small intestine, the string inside the capsule is dislodged, leaving a string that goes from the cheek to the small intestine. The capsule dislodges from the string and the string is left in place, in the mouth, esophagus, stomach and small intestine for an hour. During this time, the string rubs against the inside of the esophagus and collects eosinophil proteins. After one hour, the string is removed through the mouth and placed in preservative to save the eosinophil proteins.
Study: NCT04047394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGylated recombinant candida urate oxidase
Description: PEGylated recombinant candida urate oxidase is a combination of 20kDa linear polyethylene glycol (PEG) linked to Candida utilis recombinant uricase by succinimide succinate
Study: NCT01218230

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Pegaptanib
Description: Intravitreal pegaptanib, 0.3 mg, every 6 weeks for 3 injections and then PRN.
Study: NCT00615758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib at the dose of 150 mg orally once a day continually until progression
Study: NCT02273024

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study: NCT01594879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIrena(LNG-IUS), oral MPA
Description: 1. General Name/Brand name: Mirena - SCHERING Active ingredient: levonorgestrel 52mg Description: Mirena is a hormone-releasing T-shaped intrauterine system. A removal thread is attached to a loop at the end of the vertical stem of the T-body.~2. General Name/Brand name:Farlutal tab. 500mg/ Pfizer Active ingredient: Medroxyprogesterone Acetate
Study: NCT01262053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Intervention
Description: When a user is about to place orders on a patient, a pop up alert will show the user the name, age, sex, room number and MR# of the patient who is currently activated. The point of the alert is to display identification information about the patient as a double check for the provider to make sure he is on the correct patient. This alert will only occur once at the onset of each order session (i.e. the provider will not be alerted for every single order, but if the provider leaves the order pad and then returns, the alert will reoccur).
Study: NCT04153032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: DTZ is a calcium channel blocker for the treatment of chronic anal fissure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: DTZ is a calcium channel blocker for the treatment of chronic anal fissure